Key result
Extended LMWH thromboprophylaxis reduces post-discharge DVT risk by ~50% versus placebo after hip surgery.
Why the study?
Coagulation-related complications, including subclinical deep vein thrombosis that may cause fatal pulmonary embolism, are a frequent cause of death and morbidity following hip replacement surgery.
Does prolonged thromboprophylaxis with low-molecular-weight heparin for at least 5 weeks reduce post-discharge deep vein thrombosis and pulmonary embolism in patients undergoing hip replacement surgery?
Does prolonged thromboprophylaxis with low-molecular-weight heparin for at least 5 weeks reduce post-discharge deep vein thrombosis and pulmonary embolism in patients undergoing hip replacement surgery?
Answers are grounded in this paper and cite their sources.
Because hypercoagulability and venous stasis persist for weeks after hip replacement surgery, extending low-molecular-weight heparin prophylaxis to at least 5 weeks significantly halves post-discharge deep vein thrombosis and reduces pulmonary embolism.
Coagulation-related complications are a frequent cause of death following hip replacement surgery. Venographically-proven deep vein thrombosis (DVT) is found in a high frequency. Most cases have no symptoms. Fatal pulmonary embolism (PE) may develop from subclinical thrombi. In addition, arterial thromboses may induce serious cardiovascular events and an unknown number of patients may develop cardiorespiratory insufficiency, due to non-fatal venous PE. Finally, several patients may develop venous insufficiency. Recent prospective double-blind studies have shown that the frequency of deep vein thrombosis increased after hospital discharge in patients undergoing hip replacement surgery. Prolonged thromboprophylaxis with low-molecular-weight heparin (dalteparin or enoxaparin) is recommended for at least 5 weeks after the operation.
No takes yet. Share an insight, caveat, or question.
Ola E. Dahl (1998) conducted a review in Hip replacement surgery (total hip arthroplasty) and associated venous thromboembolism (DVT and PE). Prolonged low-molecular-weight heparin (dalteparin or enoxaparin) vs. Placebo after 1 to 2 weeks of initial in-hospital low-molecular-weight heparin prophylaxis was evaluated on Venographically-proven deep vein thrombosis (DVT) up to 5 weeks after hip replacement surgery. Prolonged thromboprophylaxis with low-molecular-weight heparin (dalteparin or enoxaparin) for up to 5 weeks reduced the frequency of post-discharge deep vein thrombosis by about 50% vs placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: